Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib and Bevacizumab in Epithelial Ovarian, Fallopian, and Peritoneal Cancer
NCT00436215Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2006
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by National Cancer Institute. Started Dec 2006; status: completed.
02
Drugs
sorafenib
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00436215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00436215.